Physician profile
Crystal Taylor Capler
NPI 1073167177
$1,945.25
in general payments reported to CMS, 2019-2025
25 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $701 · 2022: $594 · 2023: $346 · 2024: $204 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $649.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $340.42 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $257.27 | 2021-2025 | |
| Amarin Pharma, INC. | $241.71 | 2021-2022 | |
| Dexcom, INC. | $228.12 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $181.24 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $144.25 | 2021-2023 | |
| Glaxosmithkline, LLC. | $109.62 | 2021-2024 | Trelegy Ellipta |
| Stemline Therapeutics INC. | $83.07 | 2022 | |
| Alkermes, INC. | $45.24 | 2025 | Vivitrol |
| Sanofi-Aventis U.S. LLC | $32.59 | 2022 | |
| Arbor Pharmaceuticals, INC. | $30.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $29.43 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.97 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.45 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $17.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.15 | 2022 | |
| Currax Pharmaceuticals LLC | $15.19 | 2024 | Contrave |
| Merck Sharp & Dohme LLC | $14.94 | 2021 | |
| Becton, Dickinson and Company | $14.54 | 2022 | |
| Shield Therapeutics INC | $14.43 | 2023 | Accrufer |
| Idorsia Pharmaceuticals US INC | $13.32 | 2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.82 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.73 | 2023 | Rexulti |
| Angiodynamics, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Capler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.